Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4498-4500

  Von Groll, Andrea ^a   Martin, Anandi ^a   Jureen, Pontus ^b   Hoffner, Sven ^b   Vandamme, Peter ^c   Portaels, Françoise ^a   Palomino, Juan Carlos ^a   Da Silva, Pedro Almeida ^d  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c GHENT UNIVERSITY   (Belgium)

^d FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GATIFLOXACIN; MOXIFLOXACIN; OFLOXACIN; RESAZURIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CROSS RESISTANCE; GENE MUTATION; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES;

EID: 70349318563     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00287-09     Document Type: Article

References (27)

1. Alangaden, G. J., E. K. Manavathu, S. B. Vakulenko, N. M. Zvonok, and S. A. Lerner. 1995. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob. Agents Chemother. 39:1700-1703.
2. Alvirez-Freites, E. J., J. L. Carter, and M. H. Cynamon. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022-1025.
3. Antonova, O. V., D. A. Gryadunov, S. A. Lapa, A. V. Kuz'min, E. E. Larionova, T. G. Smirnova, E. Yu. Nosova, O. I. Skotnikova, L. N. Chernousova, A. M. Moroz, A. S. Zasedatelev, and M. Mikhailovich. 2008. Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips. Bull. Exp. Biol. Med. 145:108-113.
4. Escalante, P., S. Ramaswamy, H. Sanabria, H. Soini, X. Pan, O. Valiente- Castillo, and J. M. Musser. 1998. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber. Lung Dis. 79:111-118.
5. Gillespie, S. H., and O. Billington. 1999. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 44:393-395.
6. Guillemin, I., V. Jarlier, and E. Cambau. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42:2084-2088.
7. Kam, K. M., C. W. Yip, T. L. Cheung, H. S. Tang, O. C. Leung, and M. Y. Chan. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist. 12:7-11.
8. Lee, A. S., L. L. Tang, I. H. K. Lim, and S. Y. Wong. 2002. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int. J. Infect. Dis. 6:48-51.
9. Lubasch, A., I. Keller, K. Borner, P. Koeppe, and L. Hartmut. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levo- floxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44:2600-2603.
10. Martin, A., J. C. Palomino, and F. Portaels. 2005. Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays. J. Clin. Microbiol. 43:1612-1616.
11. National Committee for Clinical and Laboratory Standards. 2003. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes, vol.33, no.18. NCCLS M24-A. National Committee for Clinical and Laboratory Standards, Wayne, PA.
12. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134.
13. Pasca, M. R., P. Guglierame, F. Arcesi, M. Bellinzoni, E. De Rossi, and G. Riccardi. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48: 3175-3178.
14. Peloquin, C. A., D. J. Hadad, L. P. D. Molino, M. Palaci, W. H. Boom, R. Dietze, and J. L. Johnson. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:852-857.
15. Piddock, L. J. 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19:382-402.
16. Pitaksajjakul, P., W. Wongwit, W. Punprasit, B. Eampokalap, S. Peacock, and P. Ramasoota. 2005. Mutations in the gyrA and gyrB genes of fluoroquinolone- resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J. Trop. Med. Public Health 36(Suppl. 4):228-237.
17. Rustomjee, R., C. Lienhardt, T. Kanyok, G. R. Davies, J. Levin, T. Mthiyane, C. Reddy, A. W. Sturm, F. A. Sirgel, J. Allen, D. J. Coleman, B. Fourie, D. A. Mitchison, and the Gatifloxacin for TB (OFLOTUB) study team. 2008. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138.
18. Somasundaram, S., and N. C. Paramasivan. 2006. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Chemotherapy 52:190-195.
19. Sulochana, S., F. Rahman, and C. N. Paramasivan. 2005. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J. Chemother. 17:169-173.
20. Sun, Z., J. Zhang, X. Zhang, S. Wang, Y. Zhang, and C. Li. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 31:115-121.
21. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
22. Takiff, H. E., M. Cimino, M. C. Musso, T. Weisbrod, R. Martinez, M. B. Delgado, L. Salazar, B. R. Bloom, and W. R. Jacob, Jr. 1996. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc. Natl. Acad. Sci. USA 93:362-366.
23. van Doorn, H. R., D. D. An, M. D. de Jong, N. T. N. Lan, D. V. Hoa, H. T. Quy, N. V. V. Chau, P. M. Duy, D. Q. Tho, N. T. Chinh, J. J. Farrar, and M. Caws. 2008. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int. J. Tuberc. Lung Dis. 12:736-742.
24. World Health Organization. 2006. Guidelines for the programmatic management of drug resistant tuberculosis. WHO/HTM/TB/2006.361. World Health Organization, Geneva, Switzerland.
25. World Health Organization. 2008. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394. World Health Organization, Geneva, Switzerland.
26. Xu, C., B. N. Kreiswirth, S. Sreevatsan, J. M. Musser, and K. Drlica. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis. 174:1127-1130. (Pubitemid 26357484)
27. Zhang, Y. 2007. Advances in the treatment of tuberculosis. Clin. Pharmacol. Ther. 82:595-600.